Search
Novo Nordisk Trims Growth Projections for Obesity and Diabetes Medications; Stock Plummets Over 50% Year-to-Date
1 week ago /
Read about 0 minute
Author：小编
On Wednesday, Danish pharmaceutical behemoth Novo Nordisk revealed that sales of its top-selling weight-loss medication, Wegovy, saw an 18% year-on-year surge in the third quarter, amounting to DKK 20.35 billion. However, this figure fell marginally short of market projections. Consequently, the company has revised its annual profit outlook downward, anticipating full-year operating profit (denominated in local currency) to expand by a range of 4% to 7% in 2025, a notable decrease from its prior estimate of 10% to 16%.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
